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Abstract
Background—Cannabis use disorder (CUD) is a prevalent and impairing condition, and 
established psychosocial treatments convey limited efficacy. In light of recent findings supporting 
the efficacy of N-acetylcysteine (NAC) for CUD in adolescents, the objective of this trial was to 
evaluate its efficacy in adults.
Methods—In a 12-week double-blind randomized placebo-controlled trial, treatment-seeking 
adults ages 18–50 with CUD (N=302), enrolled across six National Drug Abuse Treatment 
Clinical Trials Network-affiliated clinical sites, were randomized in a 1:1 ratio to a 12-week course 
of NAC 1200 mg (n=153) or placebo (n=149) twice daily. All participants received contingency 
management (CM) and medical management. The primary efficacy measure was the odds of 
negative urine cannabinoid tests during treatment, compared between NAC and placebo 
participants.
Results—There was not statistically significant evidence that the NAC and placebo groups 
differed in cannabis abstinence (odds ratio = 1.00, 95% confidence interval 0.63 – 1.59; p=0.984). 
Overall, 22.3% of urine cannabinoid tests in the NAC group were negative, compared with 22.4% 
in the placebo group. Many participants were medication non-adherent; exploratory analysis 
within medication-adherent subgroups revealed no significant differential abstinence outcomes by 
treatment group.
Conclusions—In contrast with prior findings in adolescents, there is no evidence that NAC 1200 
mg twice daily plus CM is differentially efficacious for CUD in adults when compared to placebo 
plus CM. This discrepant finding between adolescents and adults with CUD may have been 
influenced by differences in development, cannabis use profiles, responses to embedded 
behavioral treatment, medication adherence, and other factors.
Keywords
cannabis; marijuana; addiction; treatment; cessation; pharmacotherapy; N-acetylcysteine
1. Introduction
One in eleven adult cannabis users develops cannabis use disorder (CUD), a syndrome with 
well characterized physiological and behavioral symptoms and associated adverse outcomes 
(Budney and Moore, 2002; Hasin et al., 2015; Volkow et al., 2014). CUD is prevalent, with 
2.5% United States adults meeting criteria in the past year, but only 13.2% of those with 
lifetime CUD participate in any treatment for the disorder (Hasin et al., 2016). For those 
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who do, evidence-based psychosocial interventions yield modest effects, with few 
individuals achieving long-term cannabis abstinence, though some evidence suggests that 
the behavioral intervention contingency management (CM), in which tangible incentives are 
provided for desired behaviors (e.g., objective indicators of cannabis abstinence) may 
enhance outcomes (Cooper et al., 2015; Gates et al., 2016). Amid increased understanding 
of the neuropharmacology of CUD, recent efforts have focused on developing 
pharmacotherapies to complement psychosocial treatments (Copeland and Pokorski, 2016; 
Marshall et al., 2014). N-acetylcysteine (NAC), available over-the-counter as an antioxidant 
supplement, restores glutamate homeostasis and reduces reinstatement of drug seeking in 
animal models of addiction and is being evaluated clinically as a potential treatment for a 
variety of substance use disorders (Baker et al., 2003; McClure et al., 2014). In an 8-week 
randomized placebo-controlled trial (RCT) for CUD in adolescents ages 15–21 (N=116) 
receiving a CM intervention and weekly medical clinician-delivered cessation counseling, 
NAC compared to placebo more than doubled the odds of abstinence during treatment, 
reflected in negative weekly urine cannabinoid tests (OR=2.4, 95% CI: 1.1–5.2, p=0.029) 
(Gray et al., 2012). While these positive findings were encouraging, a similar trial in adults 
was deemed necessary to evaluate efficacy in this age group. The present study was designed 
to replicate and extend the adolescent study’s general methods via a 12-week RCT (McClure 
et al., 2014). We hypothesized that NAC-treated adults would evidence higher rates of 
abstinence during treatment than those receiving placebo.
2. Material And Methods
2.1 Trial Design
Treatment-seeking adults with CUD were randomized, in 1:1 parallel group allocation, to 
receive a double-blind 12-week course of NAC (1200 mg) or placebo twice daily, added to a 
CM intervention and medical clinician-delivered medical management. Urine specimens 
were collected at baseline, twice weekly throughout treatment, at end-of-treatment, and at 
post-treatment follow-up for urine cannabinoid testing (UCT) by dipstick, and an aliquot 
was collected once a week for enzyme immunoassay (Abbott Laboratories, Chicago, IL) 
analysis by a central laboratory (Clinical Neurobiology Laboratory, Medical University of 
South Carolina, Charleston SC) for the primary outcome.
The study was conducted within an approved United States Food and Drug Administration 
Investigational New Drug application. The institutional review boards at participating 
centers approved the study protocol, which was overseen by an independent National 
Institute on Drug Abuse-appointed Data and Safety Monitoring Board. All participants 
provided written informed consent.
The trial was implemented across six sites within the National Drug Abuse Treatment 
Clinical Trials Network (CTN): Behavioral Health Services of Pickens County, Pickens, 
South Carolina; CODA, Portland, Oregon; University of California Los Angeles Integrated 
Substance Abuse Programs, Los Angeles, California; APT Foundation, New Haven, 
Connecticut; University of Texas Health Science Center San Antonio, San Antonio, Texas; 
University of Kentucky, Lexington, Kentucky.
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2.2 Participants
The trial enrolled treatment-seeking participants ages 18–50 meeting Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for 
cannabis dependence and submitting a positive UCT during the initial screening visit (Figure 
1) (American Psychiatric Association, 2000). Individuals with acutely unstable medical or 
psychiatric disorders, DSM-IV-TR substance dependence aside from cannabis or tobacco, 
contraindications for NAC treatment, or recent synthetic cannabinoid use were excluded. 
Recruitment, conducted between January 2014 and April 2015, occurred primarily through 
community media advertisements. Interested individuals were prescreened by phone, and 
those meeting general entry criteria were scheduled for consent and screening procedures in 
the research clinic.
2.3 General Procedures
Details of study design have been described previously (McClure et al., 2014). All 
procedures and data collection were conducted in research clinics at participating sites. At 
the baseline visit, comprehensive psychiatric and substance use diagnostic assessments, 
medical history and physical examination, and laboratory testing (urine pregnancy and drug 
tests) were performed (Sheehan et al., 1998; First et al., 2004). Timeline Follow-Back 
methods were used to assess self-reported substance use (Sobell et al., 1988; Mariani et al., 
2011).
Eligible participants were enrolled in a CM intervention, and randomized to medication 
treatment group. Participants were seen twice weekly during the 12-week treatment phase 
and a follow-up post-treatment assessment was conducted 4 weeks after treatment 
conclusion. During one weekly visit, the study medical clinician provided medical 
management and adverse event assessment, participants completed self-assessments, and 
UCT and CM procedures were completed. The other weekly visit was brief, consisting only 
of UCT and CM procedures. At multiple time points, participants and medical clinicians 
were asked to state whether they thought the participant was receiving NAC or placebo, to 
evaluate penetration of the blind. Upon the first negative UCT for a participant, the sample 
was additionally sent for synthetic cannabinoid testing (Soft Landing Labs, Elmhurst IL) to 
confirm that the participant was not substituting synthetic cannabinoids for traditional 
cannabis.
2.4 Interventions
2.4.1 Medication—Participants were randomized to a double-blind 12-week course of 
orally administered NAC 1200 mg or placebo twice daily. Randomization, conducted 
centrally through the CTN Data and Statistics Center, was on a 1:1 ratio, with stratification 
by study site and self-reported binary tobacco smoking status (yes/no), in light of prior 
research indicating poorer cannabis cessation outcomes among tobacco users (Haney et al., 
2013; Peters et al., 2014).
United States Pharmacopeia grade NAC powder was encapsulated in 600 mg quantities (two 
600 mg capsules per twice-daily dose). Matched placebo capsules were also prepared. 
Riboflavin 25 mg was added to all capsules (100 mg/day total) as a biomarker for 
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medication adherence (assessed fluorometrically by the Clinical Neurobiology Laboratory, 
Medical University of South Carolina, Charleston SC) (Malcolm et al., 2000). All capsules 
were packaged in blister packs, dispensed weekly, with individual labels for time/date of 
each dose.
2.4.2 Embedded Behavioral Treatment—All participants received CM twice weekly 
during treatment, including escalating schedules of cash reinforcement with resets, targeting 
(a) visit attendance (initial attended visit $10, escalating by $2 per subsequent visit, and reset 
to $10 after a missed visit; maximum $30 per visit), and (b) cannabis abstinence, confirmed 
by urine dipstick test (initial abstinent visit $5, escalating by $2 per subsequent visit, and 
reset to $5 after a non-abstinent or missed visit; maximum $25 per visit). Medical 
management, a low-intensity supportive intervention emphasizing cannabis abstinence, 
medication adherence, and study retention, was conducted by the medical clinician weekly 
throughout treatment (Volpicelli et al., 2001). This intervention was selected to closely 
match psychosocial procedures in the prior adolescent trial, and to reflect care that could be 
delivered in real-world medical settings.
2.5 Outcomes
2.5.1 Efficacy—UCT (<50 ng/mL considered negative) measured by the central laboratory 
during weekly clinic visits and at post-treatment follow-up, was conducted as the primary 
biological measure of cannabis use.
2.5.2 Safety/Tolerability—Adverse events were assessed at all study visits, including 
severity and relatedness to study drug or study procedures. Vital signs monitoring and urine 
pregnancy testing were additionally conducted.
2.5.3 Adherence—Pre-defined criteria for medication adherence included taking ≥80% of 
prescribed study medication per study week (assessed via weekly medication diaries and 
blister pack pill counts), confirmed by urine riboflavin level >1500 ng/mL, after subtracting 
pre-randomization riboflavin level (Herron et al., 2013).
2.6 Statistical Analyses
The primary study hypothesis was that participants randomized to NAC would be more 
likely than those randomized to placebo to have negative UCTs during treatment. An intent-
to-treat approach including all randomized participants was used. All missing UCTs (missed 
visit/dropout/lost-to-follow-up) were imputed as positive, a method that does not make the 
missing-at-random assumption and has been employed in substance use disorder treatment 
trials (Avants et al., 2000; Bickel et al., 1988; Budney et al., 2006; Johnson et al., 2007; 
Trivedi et al., 2017; Winhusen et al., 2014). A sensitivity analysis using various single 
imputation approaches was also performed to evaluate the impact of various deviations from 
the missing-at-random assumption. The scenarios included imputing missing UCTs as 
negative, using surrounding UCTs to impute missing intermittent UCTs, and the worst-case 
scenarios in which the UCT result is imputed based on treatment assignment (i.e., all 
missing UCTs in the NAC group imputed as positive and all those in the placebo group 
imputed as negative, and vice-versa).
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Based on findings from the prior adolescent trial, in which cannabis abstinence rates varied 
from 20% to 50% in the placebo arm, and consideration of a 6-site model, a sample size of 
300 was determined to provide 80% power to detect an odds ratio of 2 at the two-sided 5% 
level of significance for the primary outcome, as well as evaluation of 2- and 4-week end-of-
treatment abstinence outcomes, which were judged as clinically important for evaluation.
For the primary outcome measure, a repeated-measures logistic regression model was used 
to evaluate the odds of a negative UCT as an indicator of abstinence across all 12 weeks of 
treatment. At each week, the primary outcome was an indicator of whether the UCT at that 
visit was negative (<50 ng/mL). Because each participant contributed up to 12 outcomes to 
the model, generalized estimating equations (GEEs) were used to adjust for this correlation 
(Liang and Zeger, 1986). The primary longitudinal model included the main effects of 
treatment, time, site, and baseline tobacco smoking, as well as a time-by-treatment 
interaction. Testing of the treatment difference evaluated the overall treatment effect by 
considering the average treatment effect over all time points via a Score test. Any variables 
in this model that were not statistically significant were dropped from all further analyses. 
Wald-based odds ratios (OR) and asymptotic 95% confidence intervals (CI) were computed. 
Efficacy analyses were repeated within the subgroup of participants meeting pre-defined 
criteria for medication adherence. Pre-specified secondary analyses examined whether 
abstinence rates differed across clinical sites, baseline tobacco use status, sex, ethnicity, 
and/or race, and whether these variables were effect modifiers for the relationship between 
NAC and abstinence.
Pre-specified logistic regression models were used to analyze the odds of cannabis 
abstinence over 2- and 4-week end-of-treatment periods and at the post-treatment follow-up 
visit. GEEs were used to test for differences in the proportion of self-reported days using 
throughout treatment.
All statistical analyses were conducted using SAS version 9.3 or higher (SAS Institute Inc. 
Cary, NC, USA). Significance was set at a 2-sided p-value of 0.05.
3. Results
3.1 Enrollment and Baseline Characteristics
Of 626 individuals formally screened, 302 met criteria and were randomized (Figure 1 – 
CONSORT Diagram). Baseline demographics and clinical characteristics are presented in 
Table 1; the randomization groups did not differ in these key variables, aside from education 
(p=0.037) and employment status (p=0.004). Baseline urine cannabinoid levels were higher 
in this sample than in the prior adolescent trial (1075.1 ± SD 1430.1 versus 417.0 ± SD 
522.3 ng/mL, p<0.0001). Additionally, participants in this sample had used cannabis 15.1 ± 
SD 9.2 years, compared to 4.2 ± SD 1.8 years in the prior adolescent trial (p<0.0001). In the 
30 days prior to initial assessment, participants in this sample had used cannabis on 26.0 ± 
SD 6.2 days, compared with 23.1 ± SD 6.1 days in the prior adolescent study (p<0.0001) 
(Gray et al., 2012).
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3.2 Efficacy
The proportion of negative UCTs in the NAC and placebo groups at each visit (intent-to-
treat sample) is illustrated in Figure 2. While there was a significant effect of time on 
abstinence (p=0.001), there was no statistically significant difference between the NAC and 
placebo groups in the average odds of cannabis abstinence over time (OR=1.00, 95% CI: 
0.63–1.59, p=0.984). Overall, 22.3% of UCTs in the NAC group were negative, compared 
with 22.4% in the placebo group. The proportion of missing UCTs at study visit ranged from 
12% at week 1 to 32% at week 12, resulting in 23% of all expected UCTs being imputed. Of 
the various missing data scenarios considered in the sensitivity analysis, only the two worst-
case scenarios of imputation by treatment assignment yielded statistically significant 
treatment differences (p<0.001). For all other scenarios, the p-values were greater than 0.8. 
End-of-treatment and post-treatment analyses, as well as comparisons of self-reported 
cannabis use, similarly yielded no statistically significant evidence that NAC and placebo 
differentially affected abstinence. All tests for synthetic cannabinoids (n=107) were 
negative.
Subgroup analyses: While there was no clinical site by treatment interaction (p=0.429), site 
was a non-significant trend-level predictor of cannabis abstinence (p=0.054). Baseline 
tobacco smoking status was a strong indicator of cannabis outcomes, with tobacco smokers 
being half as likely as non-tobacco smokers to achieve cannabis abstinence during treatment 
(OR=0.52, 95% CI: 0.31–0.88, p=0.008), but there was no tobacco-by-treatment interaction 
(p=0.883) (Figure 3). Sex was not a significant predictor of cannabis abstinence, and there 
was no sex-by-treatment interaction. Hispanic/Latino participants were half as likely as non-
Hispanic/Latino participants to test negative for cannabinoids during treatment (OR=0.52, 
95% CI: 0.27–1.00, p=0.030), but there was no ethnicity-by-treatment interaction (p=0.881).
For analyses of race, three participants were excluded: two who refused to report their race 
and one whose race was unknown. Further, to optimize power, only two groups were used: 
White participants (n=176) and racial minority participants (n=123). The latter category 
included Black/African American (n=84), multiracial (n=19), Asian (n=3), American Indian/
Alaskan Native (n=2), Native Hawaiian/Pacific Islander (n=1), and Other (n=14). There was 
a trend-level race-by-treatment interaction, suggesting that while racial minority participants 
had overall lower proportions of negative UCTs, they differentially responded more 
favorably to NAC than to placebo (White NAC versus PBO OR=0.81, 95% CI: 0.46–1.44; 
racial minority NAC versus PBO OR=1.97, 95% CI: 0.84–4.63; race-by-treatment 
interaction p=0.083) (Figure 4). There was no association between race and tobacco 
smoking status (p=0.757).
The study’s primary outcome measure was examined post-hoc within participants ages 18–
21 (n=35 in the NAC group and n=23 in the placebo group), overlapping with the prior 
adolescent trial’s age range of 15–21. While the small sample size notably limited statistical 
power, within this age group NAC participants, compared to placebo participants, had 
numerically (but not statistically significantly) doubled rates of abstinence (OR=2.03, 95% 
CI: 0.70–5.86, p=0.187), a magnitude consistent with that noted in the prior adolescent trial 
(Gray et al., 2012).
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3.3 Safety/Tolerability
Adverse events were generally infrequent, without clinically significant between-group 
differences in the rates of overall or specific events. In sum, 26.8% of NAC participants and 
34.2% of placebo participants reported any treatment-emergent adverse events. Of the 7 
reported serious adverse events, 6 occurred in the placebo group and 1 occurred in the NAC 
group, and none were deemed to have a causal relationship with study medication. Body 
mass index, heart rate, and blood pressure did not change significantly over time, regardless 
of treatment group.
3.4 Blinding, Retention, and Adherence
Among participants assigned to NAC, 46.5% guessed they were receiving NAC and 53.5% 
guessed they were receiving placebo, and the medical clinician guessed that 52% were 
receiving NAC and 48% were receiving placebo. Among those assigned to placebo, 53.7% 
guessed they were receiving NAC and 46.3% guessed they were receiving placebo, and the 
medical clinician guessed that 57.3% were receiving NAC and 42.7% were receiving 
placebo. These differences were not statistically significant, and the participant and medical 
clinician agreed on guesses more often than by chance (p<0.0001).
Among randomized participants, 71.9% in the NAC group and 68.5% in the placebo group 
were retained through the end of active treatment. Availability of the primary outcome 
measure (UCT) generally mirrored weekly visit attendance, decreasing gradually over time, 
with 68.6% in the NAC group and 67.1% in the placebo group available at the end-of-
treatment visit.
Attendance-based contingent compensation (maximum possible total $610) was received by 
95.4% of NAC participants (mean total $428, median $550) and 94.6% of placebo 
participants (mean total $435, median $580). Abstinence-based contingent compensation 
(maximum possible total $490) was received by 35.3% of NAC participants (mean total $86, 
median $0) and 35.6% of placebo participants (mean total $71.80, median $0).
Following the pre-specified criteria for medication adherence, only a small subset of 
participants (n=31 in the NAC group and n=26 in the placebo group) was deemed adherent. 
Post-hoc examination of adherence based only on pill counts and self-report (taking ≥80% 
of expected medication ≥80% of the 12 weeks, regardless of riboflavin testing results), 
yielded n=87 NAC participants and n=78 placebo participants meeting criteria. The primary 
efficacy outcome was analyzed in exploratory fashion within these small, underpowered 
subgroups meeting adherence criteria, revealing no significant differential outcomes by 
treatment group. Pill counts and self-report indicated that 73% of dispensed NAC doses and 
72% of dispensed placebo doses were taken, compared to 95% and 93% taken in the prior 
adolescent trial (Gray et al., 2012).
4. Discussion
This is the largest-enrollment and first national multisite pharmacotherapy RCT for CUD, 
demonstrating the feasibility of executing these methods to evaluate candidate CUD 
treatments. The present results yielded no statistically significant evidence that NAC 1200 
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mg twice daily is differentially efficacious compared to placebo, when added to CM, for 
cannabis cessation among adults with CUD. This contrasts with the significant positive 
findings yielded in a similarly-designed prior trial in adolescents with CUD (Gray et al., 
2012). In the present trial, 22.3% of UCTs in the NAC group and 22.4% in the placebo 
group were negative, compared to 40.9% and 27.2%, respectively, in the prior adolescent 
trial. Response to NAC for CUD may potentially be age-dependent, with adolescents 
benefiting, and adults not yielding benefit at the 1200 mg twice daily dose. Whether this 
may be due to developmental differences in the course and phenomenology of CUD and 
cumulative cannabis exposure, differential effects of NAC based on stages of brain 
development, potential need for dose adjustment based on age, and/or other factors remains 
unclear, and is deserving of further examination. It is notable that participants in the present 
study presented with higher dosing, frequency, and chronicity of cannabis use compared to 
those in the prior adolescent trial.
White participants had higher placebo response rates than racial minority participants, 
possibly reflecting previously observed racial differences in response to CM (Montgomery 
et al., 2012, 2015). Racial minority participants’ poorer response to CM may have allowed 
NAC effects to emerge, as suggested by a two-fold NAC versus placebo difference in 
abstinence outcomes. Without a known biological mechanism to explain a race by treatment 
interaction, it is possible that race served as a proxy for socioeconomic or other demographic 
factors. Regardless of treatment group, participants who self-reported as tobacco smokers at 
baseline were less successful than non-tobacco smokers in achieving cannabis abstinence 
during study participation. This relationship, consistent with prior research, demonstrates 
that this may be a particularly challenging group to treat (Haney et al., 2013; Peters et al., 
2014). Hispanic/Latino participants were also less likely to achieve cannabis abstinence 
during treatment than non-Hispanic/Latino participants. Further work is needed to address 
racial and ethnic disparities in CUD treatment outcomes, and to enhance outcomes among 
individuals with co-occurring tobacco use.
The present study included CM, a powerful behavioral treatment platform. Attendance-
based CM likely contributed to study retention, and may be employed in future trials. 
Response to abstinence-based CM, particularly notable among White participants, may have 
obscured potential NAC versus placebo effects. It may be that adults with CUD (particularly 
White adults) are more responsive to abstinence-based CM than adolescents, leaving less 
opportunity for a complementary pharmacotherapy to provide added benefit. To date, NAC 
has not been tested in CUD in a randomized placebo-controlled trial without a CM platform.
While the present study included a number of strengths in design and execution, findings 
must be considered in light of limitations. While participant retention was high, medication 
adherence was poorer than in the prior adolescent trial, notably compromising the potential 
to test for efficacy in adults. Additionally, overall abstinence rates were low, especially for a 
trial that included high-magnitude CM cash rewards for abstinence, potentially reflective of 
the challenging nature of treating CUD and/or reflective of a particularly treatment-
refractory sample. It may be that a sample with less chronicity and frequency of cannabis 
use would yield greater variance and thus greater potential for detecting between-group 
differences in outcomes. Another limitation is that approximately 23% of the expected 
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UCTs were missing due to missed visits, droupout, and loss to follow-up. Single imputation 
approaches were implemented under varying assumptions about the degree of deviation 
from the missing-at-random assumption with no changes in conclusion except in the most 
extreme circumstances. While this approach allows non-ignorable missingness, the single 
imputation approach treats imputed values as observed and thus may underestimate the true 
variance.
CUD is a significant health problem with few efficacious treatments, yielding overall modest 
outcomes. Across RCTs of psychosocial and pharmacological treatments for CUD, most 
participants fail to achieve and sustain abstinence (Marshall et al., 2014; Gates et al., 2016). 
More work is needed to develop novel treatments to enhance outcomes, particularly among 
racial and ethnic minorities and among those with co-occurring tobacco use. Additionally, 
medication adherence should be more reliably enhanced and monitored, potentially via 
smartphone-delivered text prompts and video capture of medication-taking (Molton et al., 
2016; Peterson et al., 2016). While the present study does not refute NAC’s position as the 
only pharmacotherapy with positive intent-to-treat efficacy findings in adolescents with 
CUD (a finding in need of replication), it does demonstrate that, with the present dosing and 
embedded CM treatment in both arms, there is no statistically significant evidence that NAC 
is efficacious in adults with CUD.
5. Conclusions
Results suggest that prior efficacy results for NAC added to CM in adolescents may not 
extend to adults with CUD. In light of these discrepant findings, a replication trial of NAC in 
adolescents with CUD is indicated. Additional work is needed to identify and optimize novel 
treatments for CUD, to enhance medication adherence in pharmacotherapy trials, and to 
understand developmental and health-disparity factors that may influence differential CUD 
treatment outcomes by age, ethnicity, and race.
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Highlights
• N-acetylcysteine (NAC) was evaluated for cannabis use disorder (CUD) in 
adults
• All trial participants concurrently received contingency management (CM)
• NAC was previously shown to be efficacious when added to CM in 
adolescents
• The present trial did not yield evidence of efficacy of NAC added to CM in 
adults
• Additional work is needed to identify and optimize novel treatments for CUD
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Figure 1. 
CONSORT Diagram
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Figure 2. 
Intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine
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Figure 3. 
Baseline tobacco use status and intent-to-treat urine cannabinoid test results BL=Baseline; 
NAC=N-acetylcysteine
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Figure 4. 
Race and intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine
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